Despite the existence of numerous clinical practice guidelines (CPGs) for cystic fibrosis (CF), there is limited understanding of their credibility and consistency. This systematic review aims to ...

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

NARBERTH, Pennsylvania (WPVI) -- "Take A Breather Foundation" based in Narberth is a stress relief outlet for people with cystic fibrosis. Their focus is to provide a "breather" to their recipients, ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

From life-altering genetic conditions to promising new treatments, here's what you need to know about 7 inherited diseases ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 billion and an impressive 180% stock return over the past year, announced that ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Sionna Therapeutics SION) stock rises as the clinical-stage biopharma focused on cystic fibrosis therapies makes its public ...

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

The genetic disorder cystic fibrosis is unique because it can cause ... due to their genetic mutations or ability to tolerate the treatment," says Boyle. Because of this, he says, "many people ...